STAT1 and prostate carcinoma: Deregulated JAK3 and RNase L pathways in LNCaP prostate cancer cells [29], defective STAT1 and STAT2 activation in fibrosarcoma and melanoma cells [30], [31] and down-regulated IFNAR in high grade bladder cancer [32] have all been reported to disable the innate immune signaling.